Navigation Links
JNCI news brief: Breast cancer hormone receptor status and risk of a second primary tumor
Date:7/9/2009

Women with hormone receptor (HR) negative first tumors have twice as much risk for developing a second breast cancer as women with HR-positive tumors, according to a study published online July 9 in the Journal of the National Cancer Institute.

Christina A. Clarke, Ph.D., of the Northern California Cancer Center in Fremont, Calif., and colleagues examined data from the National Cancer Institute's Surveillance, Epidemiology, and End Results database to analyze whether a first tumor's estrogen receptor and progesterone receptor content and the age or race of the woman has anything to do with her risk of a second tumor.

They found that women who have had breast cancer are at increased risk of a second primary breast cancer, compared with risk in the general population. They also found that women whose first tumors were hormone-receptor negative, compared with those whose tumors were hormone-receptor positive, had almost twice as much risk of any second breast cancer, and a five-fold increase in risk of a second hormone-receptor negative breast cancer.

"Future research should focus on identifying genetic factors that predispose women to multiple HR-negative tumors to target screening, prevention, and treatment strategies more effectively," the author writes.


'/>"/>

Contact: Steve Graff
jncimedia@oxfordjournals.org
301-841-1285
Journal of the National Cancer Institute
Source:Eurekalert

Page: 1

Related medicine news :

1. In brief: New prognostic indicator for patients with IPF
2. JNCI news brief: Improving the biomarker pipeline for early cancer detection
3. JNCI news brief: Hepatitis B virus mutations may predict risk of liver cancer
4. Survival differences by race most apparent in advanced stages of breast cancer
5. MRI finds breast cancer before it becomes dangerous
6. Pathway links inflammation, angiogenesis and breast cancer
7. Drop in breast cancer incidence linked to hormone use, not mammograms
8. Breast cancer prevention practices vary across Canada
9. Eating junk food whilst pregnant and breastfeeding may lead to obese offspring
10. Acrylamide Wont Raise Breast Cancer Risk
11. New link between estrogen and breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Yorba Linda, Ca (PRWEB) , ... March 29, ... ... a standard process in many scientific laboratories. The assembly protocols involve many repetitive ... is well suited for automation, which enables the high-throughput needed, and results in ...
(Date:3/29/2017)... ... March 29, 2017 , ... The Wharton School of the University of Pennsylvania ... have made a $10 million gift to establish the Ken Moelis and Julie ... pathway to a Wharton MBA for highly-qualified Penn undergraduates whose academic and career interests ...
(Date:3/28/2017)... ... March 28, 2017 , ... For many women, getting birth control isn’t as easy as ... they either don’t have access to a health care facility or a pharmacy within 60 ... of the United States or for many who are faced with health or personal issues ...
(Date:3/28/2017)... ... ... The Thyroid Secret is a specialized 9-part documentary series ... recently launched on March 1, and Dr. Wentz discussed varied benefits and aspects ... Wentz is a licensed pharmacist and a foremost thyroid specialist. After being diagnosed ...
(Date:3/28/2017)... ... March 28, 2017 , ... Via Oncology, the leading provider ... a free, public-facing tool for analyzing the costs of various drug regimens in ... information to patients, providers, insurers and pharmaceutical companies about the estimated costs of ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... TAIPEI, Taiwan , March 28, 2017 /PRNewswire/ ... medical device company, is pleased to announce ... Series A investment of Panther Orthopedics, Inc., a ... pioneering innovative dynamic fixation solutions for orthopedic extremity ... market continues to expand rapidly, primarily due to ...
(Date:3/28/2017)...  "US Cancer Generics Market Outlook 2022" report ... trend analysis related to the emergence and integration ... in US. The report analyzes various clinical and ... generics drugs in recent years. The introduction of ... dollars for various stake holders involved US cancer ...
(Date:3/28/2017)... -- Orexigen Therapeutics, Inc. (Nasdaq: OREX ) today ... and year ended December 31, 2016. ... Orexigen, beginning with the re-acquisition of the rights to ... team at Orexigen demonstrated remarkable focus, executing on a ... our Company while rewarding us full control of our ...
Breaking Medicine Technology: